Neos Therapeutics's common stock is $50M.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company). Positive growth indicates new issuance/dilution; negative growth indicates reductions/buybacks.
As of the most recent data (September 2020), NEOS shows a common stock of $50M. That compares with $50M in the prior-year period — up 0.0% year over year. Scroll down for historical charts and peer comparison views.
Compared with the year-ago period, NEOS's common stock is now $50M (was $50M) — essentially flat versus a year earlier. Pairing that YoY change with peer averages gives a clearer picture of whether Neos Therapeutics is outperforming or lagging.
Tracking NEOS's common stock over time shows whether Neos Therapeutics is scaling, shrinking, or reshaping that part of the business. The current reading is $50M That compares with $50M in the prior-year period — up 0.0% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.
Besides this common stock page, Stockcircle has Neos Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect common stock (currently $50M) with ownership activity and broader fundamentals.
Neos Therapeutics's common stock is $50M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.